Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a new access tool make polyp removal faster and safer?

NCT ID NCT07723937

Symptom relief Sponsor: Baylor College of Medicine Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This study tests whether a device called GelPOINT® Path can improve the removal of colorectal polyps during a procedure known as endoscopic submucosal dissection (ESD). The device is designed to give doctors better access, stable air pressure, and clearer views inside the colon. Researchers will enroll 30 adults with certain types of colorectal polyps and measure how fast and safely the polyps can be removed, as well as track any complications for about four weeks afterward.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
GelPOINT® Path transanal access platform used during endoscopic submucosal dissection
What this could lead to
If successful, this approach could make polyp removal faster and safer, reducing complications and improving outcomes for patients with hard-to-reach colorectal polyps.
What could go wrong
This is a small, early feasibility study with only 30 participants, so results may not apply broadly. The device may not improve outcomes or could introduce new risks like infection or injury.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients referred for endoscopic submucosal dissection (ESD) of eligible colorectal neoplastic lesions located in the transverse colon, descending colon, rectosigmoid colon, or rectum who meet all study eligibility criteria and provide written informed consent.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 years or older. * Able and willing to provide written informed consent. * Colorectal polyps located in the transverse colon, descending colon, rectosigmoid colon, or rectum (rectal lesions located at least 2 cm from the anal verge). * Referred for endoscopic submucosal dissection (ESD) of colorectal neoplastic lesions meeting at least one of the following criteria: * Lesions with prior resection or scarring proximal to the sigmoid colon. * Granular lateral spreading tumors (GLST) \>30 mm. * Non-granular lateral spreading tumors (NGLST) \>20 mm. * Lesions with suspected submucosal invasion, including Paris classification IIa+IIc lesions or lesions with a positive non-lifting sign Exclusion Criteria: * Younger than 18 years of age. * Unable or unwilling to provide informed consent. * Pregnant. * Pedunculated lesions (Paris classification Ip or Isp). * Lesions involving the appendix or ileocecal valve

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adenoma colon polyp are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenomatous colon polyp colon adenoma colorectal adenoma polyp of large intestine rectum adenoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Adenoma colon polyp Polyp colorectal Rectal adenoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Baylor College of Medicine

    RECRUITING

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.